Canada markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
41.68-0.17 (-0.41%)
At close: 04:00PM EDT
41.68 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close41.85
Open41.64
Bid41.67 x 500
Ask41.75 x 400
Day's Range41.48 - 41.90
52 Week Range19.59 - 43.59
Volume699,206
Avg. Volume1,133,835
Market Cap7.594B
Beta (5Y Monthly)1.42
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Yahoo Finance Video

    AbbVie acquiring Cerevel Therapeutics in $8.7B deal

    AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.